Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

Andreas Hochhaus, Richard A. Larson, François Guilhot et al. · New England Journal of Medicine · 2017 · 1.2K citations · Full text

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Andrew A. Wylie, Joseph Schoepfer, Wolfgang Jahnke et al. · Nature · 2017 · 574 citations

Molecular Pharmacology, Drug Target, Medicine +3

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz et al. · Blood · 2018 · 572 citations · Full text

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure

Timothy P. Hughes, Michael J. Mauro, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 449 citations · Full text

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Andreas Hochhaus, Carlo Gambacorti‐Passerini, Camille N. Abboud et al. · Leukemia · 2020 · 82 citations · Full text